The Delhi High Court sought responses from Novartis AG, Astex Therapeutics, and others on a petition by Natco Pharma challenging the grant of a patent for breast cancer drug Ribociclib. This decision creates a compliance obligation for pharmaceutical companies in India, particularly those involved in the development and marketing of cancer treatments. The court's decision will clarify the rules on double patenting and its implications for the pharmaceutical industry. The immediate effect is on companies like Natco Pharma and Novartis, which are directly involved in the dispute.

Full News Breakdown

The dispute was triggered by the grant of a patent for Ribociclib to Novartis and Astex, which Natco alleged was an unlawful extension of patent protection. The core disagreement was over the issue of double patenting, with Natco claiming that Novartis and Astex had already secured a patent for the same invention.

• Case Name: Natco Pharma vs. Novartis AG and Astex Therapeutics

• Court: Delhi High Court

• Bench: Justice Anup Jairam Bhambhani

• Date: August 6, 2026

• Statutes Cited: Patents Act

• Primary Legal Issue: Double patenting

• Petitioner Arguments: Natco alleged that Novartis and Astex had unlawfully extended patent protection for the Ribociclib molecule by securing two patents for the same invention.

• Respondent Arguments: Novartis and Astex argued that Natco had an alternative statutory remedy under the Patents Act.

• Court Reasoning: The court will first decide whether Natco's petition is maintainable.

• Operative Order: The court sought responses from the respondents and listed the case for hearing on September 16.

• Practical Outcome: The court's decision will determine the validity of the patent grant for Ribociclib.

How Does This Affect You?

The Delhi High Court's decision to review Natco's petition has clarified that the court will examine the maintainability of challenges to patent grants on the grounds of double patenting. Pharmaceutical companies may wish to review their patent portfolios to assess potential risks. The court's decision affects companies involved in the development and marketing of cancer treatments, potentially altering their strategies for patent application and protection.

For Lawyers & Advocates

Lawyers advising pharmaceutical companies may find it useful to review the risks of double patenting with their clients. The Patents Act provides an alternative statutory remedy for challenging patent grants, which lawyers may consider when advising clients on the best course of action for patent disputes. The Delhi High Court's decision may lead to changes in the way patent applications are drafted and prosecuted in India, emphasizing the need for precision and awareness of potential double patenting issues. Lawyers may want to take into account the potential implications of double patenting challenges when advising clients on patent protection strategies.

For Law Students

The decision provides an opportunity to examine the concept of double patenting and its implications for patent protection in the pharmaceutical industry. The case teaches about how courts review regulatory power in the context of patent law and the importance of precise drafting in patent applications. The core legal doctrine or distinction students should focus on is the principle of double patenting and its implications for patent protection in the pharmaceutical industry. The decision is particularly relevant for the study of:

• Intellectual Property Law

• Patent Law

• Pharmaceutical Law

• Regulatory Compliance
  Comparable cases to study alongside this judgment are Cipla vs. Novartis (2012) and Bayer Corporation vs. Union of India (2014), which provide insight into the patentability of pharmaceutical inventions and the issue of double patenting.

For Businesses

The Delhi High Court's decision may influence the way pharmaceutical companies approach patent licensing and collaboration agreements. Businesses may want to consider the potential implications of double patenting challenges when developing and marketing new products. The decision highlights the need for careful planning and strategic patent application filing to avoid double patenting challenges. Companies may find it useful to review their patent portfolios and take into account the potential implications of double patenting.

Key Takeaways

The Delhi High Court will examine the maintainability of challenges to patent grants on the grounds of double patenting, providing clarity on the rules surrounding double patenting in India. The practice consequence is that lawyers advising pharmaceutical companies may wish to review the risks of double patenting with their clients. The enforcement consequence is that the court's decision may lead to changes in the way patent applications are examined and granted by the patent office. The outcome of the hearing on September 16 may affect the pharmaceutical industry, including how companies will adjust their patent strategies in response to the court's decision. Pharmaceutical companies may want to review their patent portfolios and seek legal advice before the next patent application filing to ensure they are aware of the potential implications of double patenting.

Source: Delhi HC seeks response on Natco's patent challenge plea